Want to see TNYA full AI Analyst Report?
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.53 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$184.45M
Enterprise Value$47.77M
Total Cash (Recent Filing)$80.89M
Total Debt (Recent Filing)$10.12M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding216,998,870
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue212.30
Enterprise Value/Gross Profit146.53
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$10.33Price Target Upside676.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$10.21M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Positive EquityA low debt-to-equity ratio and meaningful positive equity provide balance-sheet flexibility for a clinical-stage biotech. This reduces refinancing pressure, supports continued R&D spending and potential partnering or milestone-driven funding without immediate solvency concerns.
Outsourced Manufacturing StrategyMoving from owning a large manufacturing facility to CDMOs cuts long-term fixed costs and capital requirements. This improves capital efficiency, enables scalable supply for late-stage development and commercialization, and preserves internal process expertise for quality control.
Experienced New CFOBringing in a finance executive with large biopharma and biotech experience strengthens capital allocation, fundraising and investor communications. That competence helps manage R&D prioritization, structure partnerships and navigate financing during pivotal development stages.
Bears Say
High Cash BurnSustained negative operating and free cash flow indicates reliance on external capital to fund ongoing trials. Continued burn without material revenue or large milestone inflows accelerates asset depletion and raises funding and dilution risk over the medium term.
Minimal Revenue, Large LossesPractically no product-derived revenue combined with substantial net losses shows the company remains pre-commercial. Absent durable revenue streams or major partnerships, profitability is distant and program economics will rely on successful trials or external licensing.
Equity Dilution RiskExpanding the equity incentive pool enhances hiring and retention but raises potential dilution for existing shareholders. With ongoing cash burn and likely future financings, larger equity capacity can translate into more share issuance over time, pressuring per-share value.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.53 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $184.45M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.002.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 216,998,870 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went up 7.342%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (676.94% Upside)
$10.33 (676.94% Upside)
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
-80.56%
Trailing 12-Months
Asset Growth
-6.17%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$10.33
▲(676.94% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
23.34% Insiders
4.58% Mutual Funds
0.42% Other Institutional Investors
66.82% Public Companies and Individual Investors